{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:23:09Z","timestamp":1783948989421,"version":"3.55.0"},"reference-count":53,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,5,7]],"date-time":"2017-05-07T00:00:00Z","timestamp":1494115200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:p>Adenoviruses are widely used to deliver genes to a variety of cell types and have been used in a number of clinical trials for gene therapy and oncolytic virotherapy. However, several concerns must be addressed for the clinical use of adenovirus vectors. Selective delivery of a therapeutic gene by adenovirus vectors to target cancer is precluded by the widespread distribution of the primary cellular receptors. The systemic administration of adenoviruses results in hepatic tropism independent of the primary receptors. Adenoviruses induce strong innate and acquired immunity <jats:italic>in vivo<\/jats:italic>. Furthermore, several modifications to these vectors are necessary to enhance their oncolytic activity and ensure patient safety. As such, the adenovirus genome has been engineered to overcome these problems. The first part of the present review outlines recent progress in the genetic modification of adenovirus vectors for cancer treatment. In addition, several groups have recently developed cancer\u2010targeting adenovirus vectors by using libraries that display random peptides on a fiber knob. Pancreatic cancer\u2010targeting sequences have been isolated, and these oncolytic vectors have been shown by our group to be associated with a higher gene transduction efficiency and more potent oncolytic activity in cell lines, murine models, and surgical specimens of pancreatic cancer. In the second part of this review, we explain that combining cancer\u2010targeting strategies can be a promising approach to increase the clinical usefulness of oncolytic adenovirus vectors.<\/jats:p>","DOI":"10.1111\/cas.13228","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T10:16:40Z","timestamp":1488881800000},"page":"831-837","source":"Crossref","is-referenced-by-count":81,"title":["Recent advances in genetic modification of adenovirus vectors for cancer treatment"],"prefix":"10.1111","volume":"108","author":[{"given":"Yuki","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Division of Molecular and Cellular Medicine National Cancer Center Research Institute Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Nagasato","sequence":"additional","affiliation":[{"name":"Division of Molecular and Cellular Medicine National Cancer Center Research Institute Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Genetics National Cancer Center Research Institute Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-3764","authenticated-orcid":false,"given":"Kazunori","family":"Aoki","sequence":"additional","affiliation":[{"name":"Division of Molecular and Cellular Medicine National Cancer Center Research Institute Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.266"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2698"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5304.1320"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.7.3352"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp100219n"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-398342-8.00002-1"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics3030338"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2287"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3303007"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm914"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.205"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.9.5198-5205.1993"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.10.6831-6838.1996"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301701"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2012.04.008"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.3.1844-1852.1998"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.12.9706-9713.1998"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1998.9.17-2503"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/8647"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711757105"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01070-13"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3107"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.01.016"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2004.15.1157"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232458"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009823107"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01265-10"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.35"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/JVI.72.3.2022-2032.1998","article-title":"In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1\/E2A, or E1\/E4 deleted","volume":"72","author":"Lusky M","year":"1998","journal-title":"J Virol"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2001.0264"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2004.11.005"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2001.0510"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/v7112905"},{"key":"e_1_2_11_36_1","first-page":"31","article-title":"Oncolytic virus therapy for cancer","volume":"2","author":"Goldufsky J","year":"2013","journal-title":"Oncolytic Virother"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.06.009"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.3727\/096504013X13657689383139"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1899"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/10430340050016166"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3567"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(03)00138-2"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp4005854"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045550"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.1"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1760"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.66"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2016.05.002"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2016.07.003"},{"key":"e_1_2_11_50_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12029-013-9561-z","article-title":"Recent treatment advances and novel therapies in pancreas cancer: a review","volume":"45","author":"Valsecchi ME","year":"2014","journal-title":"J Gastrointest Cancer"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1159\/000347178"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5169"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.2217\/14796694.2.1.137"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.07.053"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.13228","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.13228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:04:27Z","timestamp":1695513867000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.13228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/cas.13228"],"URL":"https:\/\/doi.org\/10.1111\/cas.13228","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}